Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.75 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.64 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 5/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15269196 | 0.86 | JAK1 (0.56) | JAK1NUDT1EGLN2KDM4EALDH1A1 | |
| SCHEMBL3090231 | 0.86 | JAK1 (1.00) | JAK1NUDT1EGLN2JAK2KDM4E | |
| SCHEMBL3104923 | 0.83 | NUDT1 (0.59) | JAK1NUDT1EGLN2DYRK1A | |
| SCHEMBL3585386 | 0.81 | JAK1 (0.70) | JAK1NUDT1EGLN2JAK2KDM4E | |
| SCHEMBL5442789 | 0.80 | KDM4E (0.59) | JAK1EGLN2KDM4EALDH1A1HPGD | |
| SCHEMBL14888861 | 0.80 | JAK1 (0.66) | JAK1NUDT1EGLN2KDM4EALDH1A1 | |
| SCHEMBL7043841 | 0.80 | MAPT (0.51) | JAK1EGLN2KDM4EALDH1A1HPGD | |
| SCHEMBL30263737 | 0.80 | JAK1 (0.65) | JAK1NUDT1EGLN2JAK2KDM4E | |
| SCHEMBL2144054 | 0.79 | NUDT1 (1.00) | JAK1NUDT1EGLN2JAK2KDM4E | |
| SCHEMBL3087585 | 0.78 | NUDT1 (0.69) | JAK1NUDT1EGLN2JAK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK1 69/4885NUDT1 1120/4885EGLN2 564/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK1 69/4885NUDT1 1120/4885EGLN2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.